» Articles » PMID: 6993264

Plasma C-peptide and Serum Insulin Antibodies in Diabetic Patients Receiving Pancreatic Transplants

Overview
Journal Diabetologia
Specialty Endocrinology
Date 1980 Jul 1
PMID 6993264
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Plasma C-peptide and serum insulin antibody levels were determined in 5 diabetic patients undergoing vascularized pancreatic transplantation. The grafts functioned well at first and exogenous insulin could be withdrawn, but one to 7 weeks later the grafts were rejected. After the transplantation there was an increase in the fasting plasma C-peptide level, and B-cell stimulation with glucose or glucagon evoked a C-peptide response. Healing of ischaemic damage was reflected in an increase in the C-peptide level. During graft rejection the C-peptide level fell. Measurement of plasma C-peptide levels provides a direct index of the B-cell function of the pancreatic graft. After transplantation the insulin antibody level fell exponentially, with an apparent half life of 10-11 days, whereas the level of total IgG was variable. The results indicate that formation of insulin antibodies ceases immediately on removal of the immunogenic stimulus, that is, on withdrawal of xenogeneic insulin.

Citing Articles

Pancreas and islet transplantation. II. Clinical trials.

Sutherland D Diabetologia. 1981; 20(4):435-50.

PMID: 6786945 DOI: 10.1007/BF00253405.


Endocrine responses of type 1 (insulin-dependent) diabetic patients following successful pancreas transplantation.

Pozza G, Traeger J, Dubernard J, Secchi A, Pontiroli A, Bosi E Diabetologia. 1983; 24(4):244-8.

PMID: 6134651 DOI: 10.1007/BF00282707.


Metabolic control of type I (insulin dependent) diabetes after pancreas transplantation.

Pozza G, Bosi E, Secchi A, Piatti P, Touraine J, Gelet A Br Med J (Clin Res Ed). 1985; 291(6494):510-3.

PMID: 3928030 PMC: 1416541. DOI: 10.1136/bmj.291.6494.510.


Normalization of hepatic glucose regulation despite systemic insulin delivery. Studies in patients with pancreatic transplantation for type 1 (insulin-dependent) diabetes mellitus.

Wilczek H, Gunnarsson R, FELIG P, Ostman J, Groth C, Wahren J Diabetologia. 1991; 34(5):345-9.

PMID: 1864489 DOI: 10.1007/BF00405007.

References
1.
Groth C, Lundgren G, Gunnarsson R, Arner P, Berg B, Ostman J . Segmental pancreatic transplantation with duct ligation or drainage to a jejunal Roux-en-Y loop in nonuremic diabetic patients. Diabetes. 1980; 29 Suppl 1:3-9. DOI: 10.2337/diab.29.1.s3. View

2.
Ludvigsson J, Heding L, LARSSON Y, Leander E . C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control. Acta Paediatr Scand. 1977; 66(2):177-84. DOI: 10.1111/j.1651-2227.1977.tb07830.x. View

3.
GLIEDMAN M, Tellis V, SOBERMAN R, RIFKIN H, Freed S, Veith F . The clinical use of steroids in pancreatic transplantation. Transplant Proc. 1975; 7(1):93-8. View

4.
Groth C, Lundgren G, Arner P, Collste H, Hardstedt C, Lewander R . Rejection of isolated pancreatic allografts in patients with with diabetes. Surg Gynecol Obstet. 1976; 143(6):933-40. View

5.
Christiansen A . Radioimmunoelectrophoresis in the determination of insulin binding to IgG. Horm Metab Res. 1973; 5(3):147-54. DOI: 10.1055/s-0028-1093961. View